MedTrace Logo

A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers

NCT06675565 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2025-09-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability and PK of single ascending doses of ALN-AGT01 RVR.

Conditions

  • Healthy Volunteers

Interventions

DRUG

ALN-AGT01 RVR

ALN-AGT01 RVR will be administered subcutaneously (SC)

DRUG

Placebo

Placebo will be administered SC

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-05
Primary Completion
2025-09-08
Completion
2025-09-08

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06675565 on ClinicalTrials.gov